GE Healthcare received U.S. Food and Drug Administration (FDA) 510(k) clearance of its Q.Clear technology, which is designed to provide up to two times improvement in both quantitative accuracy and image quality in PET/CT imaging.

The Society for Cardiovascular Angiography & Interventions (SCAI) issued a list of five specific, evidence-based recommendations that should be avoided in the care of patients who have, or are at risk for, cardiovascular disease.

Patients in mild heart failure who receive a cardiac resynchronization therapy defibrillator (CRT-D) device may live longer than those implanted with a traditional implantable cardioverter defibrillator (ICD), according to research presented at the American College of Cardiology’s 63rd Annual Scientific Session.

Patients do not have to be the only beneficiaries of technological innovation. Indeed, many technological hardware and software solutions are emerging to help cardiac care providers negotiate their way through a healthcare environment that’s increasingly competitive, cost-conscious and challenging.

In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary percutaneous coronary intervention (PCI) after a heart attack, according to research presented at the American College of Cardiology’s 63rd Annual Scientific Session.